Preclinical data reported for LETI-101 show allele selective editing and mHTT reduction
March 13, 2025
Researchers from Life Edit Therapeutics Inc. recently reported preclinical data on the application of their gene editing technology Life Edit CRISPR system to Huntington’s disease (HD).
